Compounded tirzepatide was legally available in the United States from 2022 to early 2025 during the FDA drug shortage period, but enforcement deadlines have since passed and routine compounding is no longer legally supported. The FDA resolved the tirzepatide shortage in December 2024 and set enforcement deadlines of February 19, 2025 for 503A pharmacies and March 19, 2025 for 503B outsourcing facilities. On April 30, 2026, the FDA proposed permanently excluding tirzepatide from the 503B bulk drug substances list. Patients who were using compounded tirzepatide and are researching their options need accurate, current information about the regulatory status, safety concerns documented during the shortage period, and cost-effective FDA-approved alternatives now available.
What Was Compounded Tirzepatide and Why Did It Exist?
Tirzepatide (Mounjaro for type 2 diabetes, Zepbound for obesity) is a dual GIP/GLP-1 receptor agonist manufactured by Eli Lilly. When FDA-approved tirzepatide was placed on the drug shortage list in 2022 due to surging demand significantly exceeding Lilly’s manufacturing capacity, federal law permitted compounding pharmacies to produce tirzepatide preparations. This created the legal basis for a large compounded tirzepatide market that, at its peak in 2024, was estimated to account for approximately 30% of US tirzepatide supply.
Compounded tirzepatide was typically supplied as a multi-dose vial containing tirzepatide at varying concentrations, requiring patients to draw their own dose using insulin syringes. Cost during the shortage period ranged from $100 to $300 per month, compared with Zepbound’s list price of over $1,000 per month. The cost differential drove widespread adoption, particularly among patients without insurance coverage for weight management medications.
The FDA resolved the tirzepatide shortage in December 2024. Enforcement deadlines were set at February 19, 2025 for 503A state-licensed pharmacies and March 19, 2025 for 503B outsourcing facilities. These deadlines have passed. As of mid-2026, routine compounding of tirzepatide as an “essentially a copy” of Zepbound or Mounjaro is not legally supported under 503A or 503B pathways. On March 5, 2025, the U.S. District Court for the Northern District of Texas denied the Outsourcing Facilities Association’s preliminary injunction motion challenging the FDA’s determination, confirming the FDA’s position. On April 30, 2026, the FDA proposed permanently removing tirzepatide from the 503B bulk drug substances list.
The Legal Timeline: From Shortage to Enforcement
| Date | Event | Impact on Compounding |
|---|---|---|
| 2022 | FDA places tirzepatide on drug shortage list | Legal basis for compounding created; market rapidly expands |
| Oct 2024 | FDA first removes tirzepatide from shortage list | OFA immediately files lawsuit; FDA reaffirms in December 2024 |
| Dec 19, 2024 | FDA Declaratory Order: tirzepatide shortage resolved | Grace periods set: 503A until Feb 19, 2025; 503B until Mar 19, 2025 |
| Feb 19, 2025 | 503A enforcement deadline passes | State-licensed pharmacies can no longer legally compound tirzepatide copies |
| Mar 5, 2025 | District Court denies OFA preliminary injunction | FDA’s position upheld; no legal basis for continued compounding |
| Mar 19, 2025 | 503B enforcement deadline passes | Outsourcing facilities can no longer legally compound tirzepatide copies |
| Sep 2025 | FDA issues 50+ warning letters to GLP-1 compounders | Active enforcement against pharmacies still compounding tirzepatide |
| Apr 30, 2026 | FDA proposes excluding tirzepatide from 503B bulks list | Would permanently close large-scale compounding with no reinstatement pathway |
Dosing: What Compounded Tirzepatide Protocols Looked Like
This section documents the dosing protocols that were used during the shortage period, for informational purposes for patients who received compounded tirzepatide and are now transitioning to FDA-approved therapy. It does not constitute guidance for obtaining or using compounded tirzepatide, which is no longer legally available through standard channels.
Standard escalation used during shortage period
Compounded tirzepatide was typically supplied in multi-dose vials at concentrations of 5mg/mL, 10mg/mL, or custom concentrations. Escalation protocols generally mirrored the FDA-approved Zepbound schedule: 2.5mg weekly for 4 weeks, then increasing by 2.5mg every 4 weeks up to a maximum of 10mg to 15mg weekly. The critical safety distinction from FDA-approved Zepbound pens is that patients had to calculate and draw their own dose volume from the vial, creating significant potential for calculation errors.
The dosing error problem
The FDA’s 320+ adverse event reports for compounded tirzepatide primarily involved dosing errors. Unlike Zepbound’s prefilled single-dose autoinjector pens which have the dose pre-set, compounded vials required patients to know that 2.5mg at 5mg/mL concentration means drawing 0.5mL into an insulin syringe. Confusion between milligrams and milliliters, use of incorrect syringe types, and unclear compounding pharmacy labeling all contributed to overdose and underdose events.
Patients switching from compounded tirzepatide to Zepbound should work with their physician to establish the correct Zepbound starting dose based on their current dose and most recent response. Do not assume the dose number on your compounded vial corresponds directly to a Zepbound pen dose — compounded concentrations varied between pharmacies and may not equal the dose labeled. A physician review and possible re-titration from a lower dose is the safest transition approach.
Safety Concerns: What the Data Shows
The FDA received more than 320 adverse event reports related to compounded tirzepatide as of early 2025. These fall into the same categories documented for compounded semaglutide: dosing errors, potency variability, and sterility concerns.
Compounded Tirzepatide: Documented Safety Concerns
How to Get Tirzepatide Legally and Affordably in 2026
The end of legal compounding has not eliminated access options for patients who cannot afford or cannot access insurance coverage for Zepbound. Several legitimate pathways now exist.
Zepbound self-pay vial program (Eli Lilly)
Eli Lilly launched a self-pay vial program for Zepbound at significantly lower prices than the branded autoinjector pens. As of 2026, Zepbound vials are available at approximately $349 per month for 2.5mg and 5mg doses, and $499 per month for 7.5mg, 10mg, 12.5mg, and 15mg doses. These are FDA-approved, cGMP-manufactured products containing tirzepatide base — the same molecule and form used in all SURMOUNT clinical trials. Patients self-administer from vials using insulin syringes, similar to the compounded product, but with FDA-verified potency and sterility.
This program represents a meaningful cost reduction from Zepbound’s list price of over $1,000 per month and brings the cost of FDA-approved tirzepatide into a range comparable to what many patients were paying for compounded alternatives.
Insurance prior authorization
Commercial insurance coverage for Zepbound for weight management has been expanding, particularly following the Zepbound cardiovascular outcomes trial data and label expansion discussions. Prior authorization typically requires documentation of BMI criteria and at least one weight-related comorbidity. Prior authorization assistance from your prescribing physician or a patient advocacy service can significantly reduce out-of-pocket cost for patients who qualify.
Manufacturer patient assistance
Eli Lilly’s patient assistance programs (LillyInsulin, LillyCares) provide Zepbound at reduced or no cost for patients who meet income eligibility criteria. These programs are worth investigating for patients without insurance coverage who do not qualify for the self-pay vial program pricing.
Compounded Tirzepatide vs. FDA-Approved Options: 2026 Comparison
| Factor | Compounded Tirzepatide | Zepbound Self-Pay Vials | Zepbound with Insurance |
|---|---|---|---|
| Legal status (2026) | Not legally supported; enforcement active | FDA-approved; fully legal | FDA-approved; fully legal |
| Monthly cost | $100 to $300 (during shortage; currently unavailable) | $349 to $499 | $30 to $150 (copay dependent) |
| FDA quality review | None | Full NDA review and cGMP manufacturing | Full NDA review and cGMP manufacturing |
| Delivery | Multi-dose vial; patient draws dose | Single-use vials; patient draws dose | Prefilled autoinjector pens (dose pre-set) |
| Clinical trial data | None specific to compounded product | SURMOUNT program applies (same molecule) | SURMOUNT program applies |
| Availability | Not legally available through standard channels | Available through LillyDirect and authorized pharmacies | Available with prior authorization |
What If You Are Currently Using or Have Used Compounded Tirzepatide?
Patients who have been using compounded tirzepatide face three practical scenarios as of mid-2026.
Scenario 1: You still have compounded product
If you have remaining compounded tirzepatide, discuss with your physician before continuing to use it. The product’s shelf life, storage history, and potency cannot be independently verified after the fact. The safest approach is to transition to FDA-approved Zepbound vials at your physician’s earliest convenience. Do not simply stop taking the medication without discussing the transition timing with your physician — abrupt discontinuation causes rapid weight regain.
Scenario 2: Your pharmacy stopped filling compounded tirzepatide
This is the most common situation for patients affected by the enforcement deadlines. Your options are the Zepbound self-pay vial program ($349 to $499 per month), pursuing insurance prior authorization for Zepbound autoinjector pens, or applying for Lilly’s patient assistance program. Ask your prescribing physician to assist with the transition and provide the necessary documentation for prior authorization or assistance program applications.
Scenario 3: You are researching compounded tirzepatide as a new patient
As of mid-2026, obtaining legally compounded tirzepatide through a US-licensed compounding pharmacy is not a standard option. Online vendors claiming to sell compounded tirzepatide without a prescription, as a “research chemical,” or through international sources are operating outside US law and the products they sell have not been evaluated for safety or potency. The FDA has explicitly warned about counterfeit tirzepatide products entering the US market through online channels. The appropriate pathway for new patients seeking tirzepatide is through a licensed physician prescribing FDA-approved Zepbound.
Tirzepatide Efficacy: What the Clinical Evidence Shows
The efficacy data discussed here applies to FDA-approved tirzepatide (Zepbound) and cannot be assumed to extend to compounded preparations, which were not studied in clinical trials. In SURMOUNT-1, tirzepatide 15mg produced a mean body weight reduction of 20.2% at 72 weeks, with 47% of participants achieving 20% or more weight loss. The 5mg and 10mg doses produced 15.0% and 19.5% mean weight reduction respectively, providing meaningful efficacy across a range of tolerable doses.
For patients who were experiencing weight loss on compounded tirzepatide and are concerned that transitioning to FDA-approved Zepbound will affect their results: the active molecule is the same. If the compounded product contained the concentration labeled, the clinical effects should be comparable on an equivalent dose. The transition is primarily administrative and regulatory, not pharmacologic.
For a complete comparison of tirzepatide and semaglutide for weight loss including SURMOUNT-1 vs. STEP-1 trial data, see our guide on tirzepatide vs. semaglutide: which weight loss injection wins. For a full clinical breakdown of tirzepatide’s side effect profile, see our complete guide to tirzepatide side effects. For safe use protocols and Black Box Warning compliance, see our guide on safe use of tirzepatide for weight loss.
Get Access to FDA-Approved Tirzepatide Through a Supervised Programme
Advanced TRT Clinic provides physician-supervised weight management via telemedicine using FDA-approved tirzepatide (Zepbound) and semaglutide (Wegovy) only. We assist patients with prior authorization, savings programme enrollment, and transition from compounded to FDA-approved therapy. We do not prescribe compounded tirzepatide. Availability varies by state.
